FDA Approves Ezplaz as First Freeze-Dried Plasma Product in US

The Food and Drug Administration has now authorized the first room temperature plasma product for use across the United States, marking a shift in how emergency transfusion support reaches patients outside traditional hospital settings. This licensure opens pathways for rapid deployment in environments where refrigeration has long posed barriers.

Room Temperature Plasma in Emergency Care

The newly approved formulation, developed by Vascular Solutions, originates from single-donor fresh frozen plasma and undergoes lyophilization to achieve stability without cold-chain infrastructure. Clinicians can reconstitute the product quickly for adults experiencing hemorrhage when conventional plasma supplies are unavailable. This capability directly addresses gaps in prehospital, remote, and disaster-response scenarios, where minutes matter for coagulopathy correction and volume replacement.

Regulatory Pathway and Military Collaboration

Development relied on sustained cooperation between the manufacturer and defense health agencies, embedding operational requirements into the biologics license application. Evidence submitted demonstrated safety and efficacy profiles consistent with existing plasma therapies. The approach preserved commercial flexibility while prioritizing military needs, resulting in a product cleared for broader civilian integration rather than limited emergency authorization.

Ad

Operational Advantages Over Traditional Plasma

International use of similar lyophilized plasma has shown reliable performance in austere conditions. The current version incorporates single-unit sourcing and low-titer group O selection, permitting immediate administration before blood typing. Packaging eliminates risks associated with glass containers, supporting inclusion in massive transfusion protocols, warfarin reversal, and trauma-induced bleeding management. These attributes maintain the established risk profile of plasma transfusion while adding logistical flexibility.

Broader Healthcare System Impacts

Full approval enables incorporation into civilian ambulance services, rural facilities, and disaster stockpiles where frozen plasma logistics prove impractical. Economic evaluations can now assess savings from reduced refrigeration dependence and faster preparation times. Manufacturers of comparable biologics may draw on this precedent when pursuing storage innovations that prioritize durability for time-critical interventions. Further details appear in the official FDA announcement on the licensure decision.